Procter-Syntex to launch Femstat 3 OTC yeast infection cream this spring.
This article was originally published in The Tan Sheet
Executive Summary
PROCTER-SYNTEX' FEMSTAT 3 THREE-DAY OTC YEAST INFECTION CREAM TO LAUNCH in early spring, following FDA's Dec. 21 approval of an Rx-to-OTC switch application for the product. The butoconazole nitrate 2% cream is indicated for the local treatment of vaginal yeast infections. Procter-Syntex touted the product's status as the only three-day vaginal yeast infection treatment to be cleared for OTC marketing in a Dec. 27 release on the approval.